rs1217691063
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study, we have examined the SNP of methylenetetrahydrofolate reductase (MTHFR) C677T, which affects DNA methylation patterns and is linked to elevated plasma homocysteine levels in 208 patients with gemcitabine/cisplatin-treated stage IV non-small-cell lung cancer (NSCLC).
|
15217535 |
2004 |
rs1051730
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CHRNA3 (rs1051730) genotyping can improve customized chemotherapy based on tumor assessment of ERCC1 mRNA in stage IV NSCLC with PS 0.
|
19733931 |
2010 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oral afatinib (Gilotrif™) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.
|
23982599 |
2013 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oral afatinib (Gilotrif™) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.
|
23982599 |
2013 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oral afatinib (Gilotrif™) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.
|
23982599 |
2013 |
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
There is limited information available concerning the prevalence of primary T790M mutations in patients with metastatic NSCLC tumors before treatment with EGFR-TKIs.
|
24789720 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
rs372043866
|
|
|
0.020 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
rs121913236
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Herein we identified a KRAS Q22K mutation and frameshift mutations in the genes encoding serine/threonine kinase 11 (STK11) and ataxia telangiectasia mutated serine/threonine kinase (ATM) by next-generation sequencing in a patient with ALK rearrangement-positive oligo-metastatic NSCLC, whose disease progressed while on two ALK-targeted therapies.
|
25964588 |
2015 |
rs8187710
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Only one polymorphism was validated across both cohorts for an association with overall survival: the A allele of the ABCC2 polymorphism, rs8187710 (4544G>A), was associated with adverse overall survival (adjusted hazard ratio [aHR] 2.22; 95% CI: 1.2-4.0; p=0.009) among our stage IV NSCLC patients.
|
26816351 |
2016 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Conclusion Use of gefitinib for the first-line therapy of metastatic nonsmall cell lung cancer with epidermal growth factor receptor exon 19 deletions (residues 747-750) or exon 21 substitution mutation (L858R) is well-documented and supported.
|
26911477 |
2017 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Conclusion Use of gefitinib for the first-line therapy of metastatic nonsmall cell lung cancer with epidermal growth factor receptor exon 19 deletions (residues 747-750) or exon 21 substitution mutation (L858R) is well-documented and supported.
|
26911477 |
2017 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Conclusion Use of gefitinib for the first-line therapy of metastatic nonsmall cell lung cancer with epidermal growth factor receptor exon 19 deletions (residues 747-750) or exon 21 substitution mutation (L858R) is well-documented and supported.
|
26911477 |
2017 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
|
26980062 |
2016 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
|
26980062 |
2016 |
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
|
26980062 |
2016 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
|
27283860 |
2016 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
|
27283860 |
2016 |
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
|
27784815 |
2016 |
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
|
28367058 |
2017 |